Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; University of Sydney, Sydney, NSW, Australia.
Semin Hematol. 2019 Apr;56(2):131-138. doi: 10.1053/j.seminhematol.2018.07.004. Epub 2018 Aug 23.
In the 60 years since the recognition of acute promyelocytic leukemia as a distinct entity, outcomes for patients have improved dramatically. This has occurred partly because of improvements in supportive care, and partly because treatment has diverged from reliance on standard antileukemic chemotherapy to the use of agents that are specifically targeted at the molecular events responsible for initiating and maintaining the disease. However early death remains a significant barrier to cure, especially for patients who fall outside the selection biases imposed by clinical trials. This review will focus on changes to clinical practice that have been adopted to reduce the risk of failure.
自急性早幼粒细胞白血病被确认为一种独特实体以来的 60 年中，患者的预后得到了显著改善。这部分是由于支持性护理的改善，部分是由于治疗已经从依赖标准的抗白血病化疗转向使用专门针对引发和维持疾病的分子事件的药物。然而，早期死亡仍然是治愈的一个重大障碍，特别是对于那些不符合临床试验所施加的选择偏见的患者。这篇综述将重点介绍为降低失败风险而采用的临床实践变化。
